UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

(Amendment No. 2)¹

Centessa Pharmaceuticals plc
(Name of Issuer)
Ordinary Shares, nominal value £0.002 per share
(Title of Class of Securities)
152309100
(CUSIP Number)
September 30, 2024
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☑ Rule 13d-1(c)
□ Rule 13d-1(d)
The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in prior cover page.
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act however, <i>see</i> the <i>Notes</i>).

1	NAME OF REPOR	RTING PERSON	
	Biotechnolog	gy Value Fund, L.P.	
2		PROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠ (b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	Delaware		
NUMBER OF SHARES BENEFICIALLY	5	SOLE VOTING POWER 0	
OWNED BY EACH REPORTING	6	SHARED VOTING POWER 0	
PERSON WITH	7	SOLE DISPOSITIVE POWER 0	
	8	SHARED DISPOSITIVE POWER	
9	AGGREGATE AM	0 IOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
,	0	DOWN BENEFICIALLY OWNER BY ENGINEER ON THE ON THE OWNER BY	
10	CHECK BOX IF T	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11		ASS REPRESENTED BY AMOUNT IN ROW (9)	
12	0% TYPE OF REPOR	TING DEDSON	-
12	PN	HING FERSON	

1	NAME OF REPOR	TING PERSON	
	DVETCRIT	C	
2	BVF I GP LL	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵
	CHECK THE ALL	ROTRINIE BOX II ATMENDER OF A GROOT	(a) ⊡ (b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	Delaware		
NUMBER OF	Delaware 5	SOLE VOTING POWER	
SHARES			
BENEFICIALLY		0	
OWNED BY EACH	6	SHARED VOTING POWER	
REPORTING		0	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		0	
	8	SHARED DISPOSITIVE POWER	
		0	
9	AGGREGATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
10	0	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	П
10	CHECK BOX IF 1	HE AUGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)	
	0%		
12	TYPE OF REPORT	TING PERSON	
	00		
	00		

1	NAME OF REPOR	RTING PERSON	
	Biotechnolog	gy Value Fund II, L.P.	
2		PROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠ (b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR	R PLACE OF ORGANIZATION	
	Delaware		
NUMBER OF SHARES BENEFICIALLY	5	SOLE VOTING POWER 0	
OWNED BY EACH REPORTING	6	SHARED VOTING POWER 0	
PERSON WITH	7	SOLE DISPOSITIVE POWER 0	
	8	SHARED DISPOSITIVE POWER	
9	AGGREGATE AN	0 MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	0		
10	CHECK BOX IF 1	THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CL	ASS REPRESENTED BY AMOUNT IN ROW (9)	
12	0% TYPE OF REPOR	TIMO BED COM	
12	PN	TING PERSON	

1	NAME OF REPORT	TING PERSON	
	BVF II GP LI		
2	CHECK THE APPR	COPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠ (b) □
			(0) 🗆
3	SEC USE ONLY		
	CAMPAGE VALVE OF	N. LOD OD OD OLIVIZATION	
4	CITIZENSHIP OR I	PLACE OF ORGANIZATION	
	Delaware		
NUMBER OF	5	SOLE VOTING POWER	
SHARES			
BENEFICIALLY OWNED BY		0 SHARED VOTING POWER	
EACH	6	SHARED VOTING POWER	
REPORTING		0	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		0	
	8	0 SHARED DISPOSITIVE POWER	
	8	SHARLD DISTOSITIVE TOWER	
		0	
9	AGGREGATE AMO	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	0		
10		HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
	DED GEVIE OF ST		
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)	
	0%		
12	TYPE OF REPORT	ING PERSON	
	00		

1	NAME OF REPOR	RTING PERSON	
	Biotechnolog	gy Value Trading Fund OS LP	
2		PROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠ (b) □
3	SEC USE ONLY		
4	CITIZENSHIP OF	R PLACE OF ORGANIZATION	
	Cayman Isla	nds	
NUMBER OF SHARES BENEFICIALLY	5	SOLE VOTING POWER 0	
OWNED BY EACH REPORTING	6	SHARED VOTING POWER 0	
PERSON WITH	7	SOLE DISPOSITIVE POWER 0	
	8	SHARED DISPOSITIVE POWER	
9	AGGREGATE AN	0 MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
,	0	TOURT BENEFICIALLY OWNED BY LACTINE ORTHOTERSON	
10	CHECK BOX IF T	THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11		ASS REPRESENTED BY AMOUNT IN ROW (9)	
12	0% TYPE OF REPOR	TING DED SON	-
12	PN	I ING PERSON	

	NAME OF PERON	OMPLIA DEDAGAY	
1	NAME OF REPOR	RTING PERSON	
	BVF Partner		
2	CHECK THE APP	PROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠
			(b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	Cayman Isla	nds	
NUMBER OF	5	SOLE VOTING POWER	
SHARES			
BENEFICIALLY		0	
OWNED BY	6	SHARED VOTING POWER	
EACH			
REPORTING		0	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		0	
	8	SHARED DISPOSITIVE POWER	
		0	
9	AGGREGATE AM	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	0		
10	CHECK BOX IF T	THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CL	ASS REPRESENTED BY AMOUNT IN ROW (9)	
	0%		
12	TYPE OF REPOR	TING PERSON	
	CO		

	1111 (E OF DEDO	TTD 10 PER COV	 1
1	NAME OF REPORTING PERSON		
	BVF GP Hol		
2	CHECK THE APP	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠
			(b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	Delaware		
NUMBER OF	5	SOLE VOTING POWER	
SHARES			
BENEFICIALLY		0	
OWNED BY	6	SHARED VOTING POWER	
EACH			
REPORTING		0	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		0	
	8	SHARED DISPOSITIVE POWER	
9	A CODECATE AN	0 OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
9	AGGREGATE AM	IOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	0		
10		HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	П
10	CHECK BOX II' I	THE AGGREGATE AMOUNT IN NOW (3) EXCEODES CERTAIN SHARES	
11	PERCENT OF CI	ASS REPRESENTED BY AMOUNT IN ROW (9)	
11	I ERCENT OF CLA	100 REFERENCE DE MITOURE IN ROW (3)	
	0%		
12	TYPE OF REPORT	TING PERSON	
12	1112 OF REFORM		
	00		

1	NAME OF REPOR	TTING PERSON	
	BVF Partners	s L P	
2		ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠ (b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	Delaware		
NUMBER OF SHARES BENEFICIALLY	5	SOLE VOTING POWER 0	
OWNED BY EACH REPORTING	6	SHARED VOTING POWER 0	
PERSON WITH	7	SOLE DISPOSITIVE POWER 0	
	8	SHARED DISPOSITIVE POWER	
9	AGGREGATE AM	0 OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
,	0	DEVELOPMENT OWNER BY EXCURACION TO TEXAULT	
10	CHECK BOX IF T	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)	
- 12	0%	EDIC DEDGOV	
12	PN, IA	IING PERSON	

1	NAME OF BEDOE	CTRIC DEDGON		
1	NAME OF REPOR	NAME OF REPORTING PERSON		
	DITE			
	BVF Inc.		7	
2	CHECK THE APP	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠	
			(b) □	
3	SEC USE ONLY			
	CITIZENGLID OR	DI A CE OF OD CANTZATION		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION		
	Delesses			
NUMBER OF	Delaware 5	SOLE VOTING POWER		
SHARES	3	SOLE VOTING POWER		
BENEFICIALLY		0		
OWNED BY	6	SHARED VOTING POWER		
EACH	0	SHARED VOTINGTOWER		
REPORTING		0		
PERSON WITH	7	SOLE DISPOSITIVE POWER		
	,			
		0		
	8	SHARED DISPOSITIVE POWER		
		0		
9	AGGREGATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	0			
10	CHECK BOX IF T	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)		
	00/			
12	0%	FINC REPOON		
12	TYPE OF REPORT	IING PEKSUN		
	СО			

-			
1	NAME OF REPO	RTING PERSON	
	Mark N. Lar		
2	CHECK THE API	PROPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵
			(b) □
3	SEC USE ONLY		
4	CITIZENSHIP OF	R PLACE OF ORGANIZATION	
	United State	S	
NUMBER OF	5	SOLE VOTING POWER	
SHARES			
BENEFICIALLY		0	
OWNED BY	6	SHARED VOTING POWER	
EACH			
REPORTING		0	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		0	
	8	SHARED DISPOSITIVE POWER	
		0	
9	AGGREGATE AN	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	0		
10	CHECK BOX IF	THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
		• • • • • • • • • • • • • • • • • • • •	
11	PERCENT OF CL	ASS REPRESENTED BY AMOUNT IN ROW (9)	
		· /	
	0%		
12	TYPE OF REPOR	TING PERSON	
	IN		
	<u> </u>		

Item 1(a). Name of Issuer:

Centessa Pharmaceuticals plc, incorporated under the laws of England and Wales (the "Issuer").

Item 1(b). Address of Issuer's Principal Executive Offices:

1 Ashley Road, 3rd Floor Altrincham, Cheshire WA14 2DT United Kingdom

Item 2(a). Name of Person Filing

Item 2(b). Address of Principal Business Office or, if None, Residence

Item 2(c). Citizenship

Biotechnology Value Fund, L.P. ("BVF") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

BVF I GP LLC ("BVF GP") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

Biotechnology Value Fund II, L.P. ("BVF2") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

BVF II GP LLC ("BVF2 GP") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

Biotechnology Value Trading Fund OS LP ("Trading Fund OS") PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands Citizenship: Cayman Islands

BVF Partners OS Ltd. ("Partners OS") PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands Citizenship: Cayman Islands

BVF GP Holdings LLC ("BVF GPH") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

BVF Partners L.P. ("Partners") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

BVF Inc.

44 Montgomery St., 40th Floor San Francisco, California 94104

Citizenship: Delaware

Mark N. Lampert ("Mr. Lampert") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: United States

Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."

Item 2(d). **Title of Class of Securities:**

Ordinary Shares, nominal value £0.002 per share (the "Shares"). The Reporting Persons previously owned American Depositary Shares of the Issuer representing Shares.

Item 2(e). **CUSIP Number:**

152309100

Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

		/x/	Not applicable.
(a	a)	//	Broker or dealer registered under Section 15 of the Exchange Act.
(1	b)	//	Bank as defined in Section 3(a)(6) of the Exchange Act.
(0	e)	//	Insurance company as defined in Section 3(a)(19) of the Exchange Act.
(0	d)	//	Investment company registered under Section 8 of the Investment Company Act.
(6	e)	//	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
(1	f)	//	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
()	g)	//	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
(1	h)	//	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
(i		//	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
(j	j)	//	Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
(1	k)	//	Group, in accordance with Rule $240.13d-1(b)(1)(ii)(K)$. If filing as a non-U.S. institution in accordance with Rule $240.13d-1(b)(1)(ii)(J)$, please specify the type of institution:

Item 4. Ownership

As of the close of business on September 30, 2024, the Reporting Persons no longer beneficially owned any securities of the Issuer.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the Shares, check the following [X].

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable.

Item 7. Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable.

Item 8. Identification and Classification of Members of the Group.

See Exhibit 99.1 to the Schedule 13G filed with the Securities and Exchange Commission on June 16, 2022.

Item 9. Notice of Dissolution of Group.

Not Applicable.

Item 10. Certifications.

By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: November 14, 2024 BIOTECHNOLOGY VALUE FUND, L.P. BIOTECHNOLOGY VALUE TRADING FUND OS LP BVF I GP LLC, its general partner By: BVF Partners L.P., its investment manager BVF Inc., its general partner By: /s/ Mark N. Lampert Mark N. Lampert /s/ Mark N. Lampert Chief Executive Officer Mark N. Lampert President BVF I GP LLC BVF GP HOLDINGS LLC /s/ Mark N. Lampert By: Mark N. Lampert /s/ Mark N. Lampert Chief Executive Officer Mark N. Lampert Chief Executive Officer BIOTECHNOLOGY VALUE FUND II, L.P. BVF PARTNERS L.P. BVF II GP LLC, its general partner By: BVF Inc., its general partner By: /s/ Mark N. Lampert Mark N. Lampert /s/ Mark N. Lampert Chief Executive Officer Mark N. Lampert President BVF II GP LLC BVF INC. By: /s/ Mark N. Lampert By: /s/ Mark N. Lampert Mark N. Lampert Chief Executive Officer Mark N. Lampert President BVF PARTNERS OS LTD. /s/ Mark N. Lampert

BVF Partners L.P., its sole member BVF Inc., its general partner

By: /s/ Mark N. Lampert Mark N. Lampert

President

MARK N. LAMPERT

15